Care of the asplenic patient

New England Journal of Medicine

Volumn 371, Issue 4, 2014, Pages 349-356

  Rubin, Lorry G ^a,b   Schaffner, William ^c  

^a Northwell Health   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PENICILLIN V; PLACEBO; PNEUMOCOCCUS VACCINE; ANTIINFECTIVE AGENT;

ABDOMINAL INJURY; ANTIBIOTIC PROPHYLAXIS; ASPLENIA; BACTERIAL CLEARANCE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; FEVER; HUMAN; INFECTION PREVENTION; INFECTION RISK; NONHUMAN; PATIENT CARE; PNEUMOCOCCAL INFECTION; POSTOPERATIVE INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SPLENECTOMY; SURGICAL RISK; TRAFFIC ACCIDENT; TREATMENT INDICATION; TREATMENT PLANNING; CONGENITAL MALFORMATION; IMMUNE DEFICIENCY; MALE; SEPSIS; SPLEEN; VACCINATION; YOUNG ADULT;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; FEVER; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; MALE; PRACTICE GUIDELINES AS TOPIC; SEPSIS; SPLEEN; SPLENECTOMY; VACCINATION; YOUNG ADULT;

EID: 84904579644     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcp1314291     Document Type: Article

References (46)

1. Bisno AL, Freeman JC. The syndrome of asplenia, pneumococcal sepsis, and disseminated intravascular coagulation. Ann Intern Med 1970;72:389-93.
2. Latos DL, Stone WJ. Fulminant pneumococcal bacteremia in an asplenic chronic hemodialysis patient. Johns Hopkins Med J 1978;143:165-8. (Pubitemid 9073377)
3. Torres J, Bisno AL. Hyposplenism and pneumococcemia: visualization of Diplococcus pneumoniae in the peripheral blood smear. Am J Med 1973;55:851-5.
4. Katz SC, Pachter HL. Indications for splenectomy. Am Surg 2006;72:565-80. (Pubitemid 46940707)
5. Pearson HA, McIntosh S, Ritchey AK, Lobel JS, Rooks Y, Johnston D. Developmental aspects of splenic function in sickle cell diseases. Blood 1979;53:358-65. (Pubitemid 9140393)
6. Lutwick LI. Infections in asplenic patients. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 7th ed. Philadelphia: Churchill Livingstone Elsevier, 2010:3865-73.
7. Di Sabatino A, Carsetti R, Corazza GR. Post-splenectomy and hyposplenic states. Lancet 2011;378:86-97.
8. Bisharat N, Omari H, Lavi I, Raz R. Risk of infection and death among post-splenectomy patients. J Infect 2001;43:182-6. (Pubitemid 34211099)
9. Singer DB. Postsplenectomy sepsis. In: Rosenberg HS, Bolande RP, eds. Perspectives in pediatric pathology. Vol. 1. Chicago: Year Book Medical, 1973:285-311.
10. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia: a randomized trial. N Engl J Med 1986;314:1593-9. (Pubitemid 16118215)
11. McCavit TL, Xuan L, Zhang S, Flores G, Quinn CT. Hospitalization for invasive pneumococcal disease in a national sample of children with sickle cell disease before and after PCV7 licensure. Pediatr Blood Cancer 2012;58:945-9.
12. Adamkiewicz TV, Silk BJ, Howgate J, et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. Pediatrics 2008;121:562-9.
13. Halasa NB, Shankar SM, Talbot TR, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 2007;44:1428-33. (Pubitemid 46801584)
14. National Hospital Discharge Survey. Atlanta: Centers for Disease Control and Prevention (http://www.cdc.gov/nchs/nhds/nhds-tables.htm#detailed).
15. Sickle Cell Association of America. Research and screening (http://www.sicklecelldisease.org/index.cfm?page=research-screening).
16. Styrt B. Infection associated with asplenia: risks, mechanisms, and prevention. Am J Med 1990;88:33N-42N.
17. Kristinsson SY, Gridley G, Hoover RN, Check D, Landgren O. Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up. Haematologica 2014; 99:392-8.
18. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010;201:32-41.
19. Ellison AM, Ota KV, McGowan KL, Smith-Whitley K. Epidemiology of bloodstream infections in children with sickle cell disease. Pediatr Infect Dis J 2013;32:560-3.
20. Eraklis AJ, Kevy SV, Diamond LK, Gross RE. Hazard of overwhelming infection after splenectomy in childhood. N Engl J Med 1967;276:1225-9.
21. Evans DI. Postsplenectomy sepsis 10 years or more after operation. J Clin Pathol 1985;38:309-11. (Pubitemid 15134087)
22. Brown EJ, Hosea SW, Frank MM. The role of the spleen in experimental pneumococcal bacteremia. J Clin Invest 1981;67:975-82. (Pubitemid 11090535)
23. Hosea SW, Brown EJ, Hamburger MI, Frank MM. Opsonic requirements for intravascular clearance after splenectomy. N Engl J Med 1981;304:245-50. (Pubitemid 11166875)
24. Rubin LG. Anticapsular antibody requirements for protection against experimental Haemophilus inf luenzae type b bacteremia after splenectomy. Infect Immun 1988;56:984-6. (Pubitemid 18092162)
25. Waldman JD, Rosenthal A, Smith AL, Shurin S, Nadas AS. Sepsis and congenital asplenia. J Pediatr 1977;90:555-9. (Pubitemid 8083170)
26. Zarrouk V, Habibi A, Zahar JR, et al. Bloodstream infection in adults with sickle cell disease: association with venous catheters, Staphylococcus aureus, and bone-joint infections. Medicine (Baltimore) 2006;85:43-8. (Pubitemid 43884286)
27. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010;59(RR-11):1-18.
28. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012;61:816-9.
29. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2013;62:521-4.
30. Lesprit P, Pédrono G, Molina JM, et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 2007;21:2425-34.
31. Vaccines and Related Biological Products Advisory Committee (VRBPAC) adult indication briefing document: Prevnar 13. Silver Spring, MD: Food and Drug Administration, 2011 (http://www.fda.gov/downloads/advisorycommittees/ committeesmeetingmaterials/bloodvaccinesandotherbiologics/ vaccinesandrelatedbiologicalproductsadvisorycommittee/ucm279680.pdf).
32. Shatz DV, Schinsky MF, Pais LB, Romero-Steiner S, Kirton OC, Carlone GM. Immune responses of splenectomized trauma patients to the 23-valent pneumococcal polysaccharide vaccine at 1 versus 7 versus 14 days after splenectomy. J Trauma 1998;44:760-5.
33. Shatz DV, Romero-Steiner S, Elie CM, Holder PF, Carlone GM. Antibody responses in postsplenectomy trauma patients receiving the 23-valent pneumococcal polysaccharide vaccine at 14 versus 28 days postoperatively. J Trauma 2002;53:1037-42. (Pubitemid 35435087)
34. Konradsen HB, Rasmussen C, Ejstrud P, Hansen JB. Antibody levels against Streptococcus pneumoniae and Haemophilus influenzae type b in a population of splenectomized individuals with varying vaccination status. Epidemiol Infect 1997;119:167-74. (Pubitemid 27474797)
35. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013;62(RR-2):1-28.
36. MacNeil JR, Rubin L, McNamara L, et al. Use of MenACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2013. MMWR Morb Mortal Wkly Rep 2014;63:527-30.
37. Wong KK, Jain S, Blanton L, et al. Influenza-associated pediatric deaths in the United States, 2004-2012. Pediatrics 2013;132:796-804.
38. Schwarzmann SW, Adler JL, Sullivan RJ Jr, Marine WM. Bacterial pneumonia during the Hong Kong influenza epidemic of 1968-1969. Arch Intern Med 1971;127:1037-41.
39. Pickering LK, Baker CJ, Kimberlin DW, Long SS. Red book: 2012 report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2012:88-90, 581-2.
40. Falletta JM, Woods GM, Verter JI, et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia: Prophylactic Penicillin Study II. J Pediatr 1995;127:685-90.
41. Rubin LG. Capnocytophaga species. In: Long SS, Pickering LK, Prober CG, eds. Principles and practice of pediatric infectious diseases. 4th ed. Edinburgh: Elsevier Saunders, 2012:880-1.
42. Kroger AT, Sumaya CV, Pickering LK, Atkinson WL. General recommendations on immunization - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011;60(RR-2):1-64.
43. Prevention and control of haemophilus influenzae type b disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014;63(RR-1):1-14.
44. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014;58:309-18.
45. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014;58(3):e44-e100.
46. Davies JM, Lewis MPN, Wimperis J, Rafi I, Ladhani S, Bolton-Maggs PHB. Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: prepared on behalf of the British Committee for Standards in Haematology by a working party of the Haemato-Oncology Task Force. Br J Haematol 2011;155:308-17.